Anupam Chahal, MD
Rheumatology · Manteca
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 26 years
- Graduated 2000
Offices
1 location
Looking this up.
Hospitals listed: Adventist Health Sonora · Doctors Hospital of Manteca · Sutter Medical Center, Sacramento · Sutter Roseville Medical Center · Sutter Tracy Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chahal’s office at (209) 284-4561 to ask if they take your plan before you enroll.
California Medical Board record
Licence A121284 · Current
Licensed to practise in California · since 2012 · expires 2027-08-31 · Baba Farid University of Health Sciences, Government Medical College, Amritsar.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health SonoraSonora, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative wound dehiscence rate: 3.5 (2.04 to 4.96) · 288 cases, Jul 2022 – Jun 2024Worse than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 1.3 (1 to 1.6) · 1,004 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- Doctors Hospital of MantecaManteca, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency departmentPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 55% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.165, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
- Sutter Tracy Community HospitalTracy, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Sonora
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative wound dehiscence rateComplications and deaths | 3.5 (2.04 to 4.96) · 288 cases | Worse | Jul 2022 – Jun 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.6) · 1,004 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.15 (0.14 to 2.16) · 582 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.5 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.91 (123.44 to 242.37) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15 · 433 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,364 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 3,671 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.07 to 0.48) · 3,602 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.24 to 5.59) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.59 (0.98 to 4.2) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.97 (0 to 16.16) · 306 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.72 (1.85 to 9.58) · 277 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.06) · 2,750 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.614 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 209 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -23.8 · 255 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.4 · 455 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 381 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (4.3 to 8.1) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (9.1 to 14.7) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.3) · 1,835 cases | No different | Jan 2022 – Dec 2024 |
What patients said (326 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Doctors Hospital of Manteca
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.165 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.09) · 230 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.49 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 30 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.5 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 700 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.33 (0.1 to 0.56) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,462 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.24 to 6.39) · 137 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.28 (0.57 to 4) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.23 to 3.28) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,152 cases | No different | Jul 2022 – Jun 2024 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.4 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 67.3 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 60 · 183 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.4 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.2 to 16.8) · 379 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (339 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 68% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 65% |
| Doctors "always" treated them with courtesy and respect | 76% |
| Patients who gave a rating of "9" or "10" (high) | 56% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 62% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 55% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Tracy Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 2 better, 5 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.28 (0.21 to 2.34) · 363 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.41 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.3 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 156 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.6 · 51 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 835 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,800 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,820 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.09 (0.6 to 5.57) · 291 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0 to 3.16) · 138 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.51 to 3.87) · 274 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (0 to 17.04) · 145 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.93 (0.72 to 9.15) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1.34) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.981 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.796 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.8 · 194 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -47.9 · 145 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.1 · 154 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 42 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.3 to 16.7) · 504 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 104 cases | No different | Jan 2024 – Dec 2024 |
What patients said (443 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$3,269,093
Medicare paid this office $3,269,093 for 521 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 60 | $1,176,963 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 62 | $841,159 | None |
| Return visit (30+ min) | 376 | $85,880 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 96 | $80,378 | $112 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 86 | $75,923 | $61 |
See all 16 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 60 | $1,176,963 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 62 | $841,159 | None |
| Return visit (30+ min) | 376 | $85,880 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 96 | $80,378 | $112 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 86 | $75,923 | $61 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 11 | $67,259 | $16 |
| Injection, denosumab, 1 mg | 21 | $45,842 | None |
| Short return visit (20+ min) | 216 | $20,055 | $66 |
| New patient visit (45+ min) | 105 | $13,461 | $128 |
| Administration of chemotherapy into vein, each additional hour | 30 | $4,691 | $24 |
| Aspiration and/or injection of fluid from large joint | 50 | $4,342 | $58 |
| Aspiration and/or injection of fluid from small joint | 22 | $741 | $30 |
| Telephone medical discussion with physician, 5-10 minutes | 14 | $714 | $48 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 88 | $501 | None |
| Injection of drug or substance under skin or into muscle | 29 | $460 | $11 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 28 | $402 | $13 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration and/or injection of fluid from large joint | 163 | 86 | 70 | 114 | 104 | 75 |
| Aspiration and/or injection of fluid from small joint | 38 | 23 | 22 | 38 | 29 | 25 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
521 Original Medicare patients in 2024. Average age 72 · Under 65 17% · 85 and older 9% · Women 74% · Also on Medicaid 40% · Health risk score 1.39. Above the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Diabetes 33% · Coronary heart disease 21% · Chronic kidney disease 21% · Depression 21% · COPD 16% · Atrial fibrillation 16% · Heart failure 13% · Cancer 13% · Stroke 7% · Dementia 3%.
The office billed $12,457,197, Medicare allowed $4,129,097 and paid $3,269,093; for 329,179 services of 44 kinds; $2,968,575 of it was for drugs given in the office and $300,518 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 521 | 329,179 | 72 | 1.39 | $12,457,197 | $3,269,093 |
| 2023 | 505 | 321,266 | 71 | 1.26 | $5,547,465 | $3,519,679 |
| 2022 | 525 | 316,249 | 71 | 1.26 | $5,850,447 | $3,169,684 |
| 2021 | 517 | 207,248 | 71 | 1.29 | $5,866,090 | $3,048,681 |
| 2020 | 566 | 187,140 | 72 | 1.37 | $12,037,081 | $2,924,344 |
| 2019 | 703 | 205,065 | 71 | 1.31 | $15,044,272 | $3,430,474 |
| 2018 | 701 | 98,094 | 72 | 1.32 | $5,782,870 | $1,631,974 |
| 2017 | 199 | 7,159 | 67 | 1.33 | $174,889 | $94,344 |
| 2016 | 40 | 89 | 62 | 1.40 | $27,070 | $8,823 |
| 2014 | 71 | 149 | 66 | 1.34 | $25,442 | $7,326 |
| 2013 | 111 | 479 | 67 | 1.26 | $72,188 | $27,295 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 68 | $1,337,791 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 66 | $922,505 | None |
| Administration of chemotherapy into vein, 1 hour or less | 93 | $80,371 | $111 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 85 | $72,852 | $62 |
| Return visit (30+ min) | 324 | $71,239 | $93 |
| Injection, denosumab, 1 mg | 19 | $35,153 | None |
| Short return visit (20+ min) | 296 | $33,045 | $64 |
| New patient visit (45+ min) | 79 | $9,188 | $116 |
| Aspiration and/or injection of fluid from large joint | 63 | $5,724 | $55 |
| Administration of chemotherapy into vein, each additional hour | 21 | $3,607 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 41 | $2,254 | $54 |
| New patient visit (30+ min) | 20 | $1,616 | $81 |
| Injection of drug or substance under skin or into muscle | 44 | $905 | $12 |
| Aspiration and/or injection of fluid from small joint | 22 | $738 | $25 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 96 | $589 | None |
2022: 14 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 61 | $1,200,864 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 73 | $1,104,032 | None |
| Return visit (30+ min) | 333 | $71,755 | $97 |
| Injection, denosumab, 1 mg | 21 | $35,993 | None |
| Short return visit (20+ min) | 312 | $34,340 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 76 | $31,292 | $58 |
| Injection of drug or substance under skin or into muscle | 122 | $15,918 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $11,014 | $111 |
| New patient visit (45+ min) | 81 | $10,453 | $129 |
| Aspiration and/or injection of fluid from large joint | 54 | $5,633 | $49 |
| New patient visit (30+ min) | 29 | $2,575 | $89 |
| Administration of chemotherapy into vein, each additional hour | 14 | $2,242 | $25 |
| Aspiration and/or injection of fluid from small joint | 24 | $1,366 | $36 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 88 | $576 | None |
2021: 15 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 58 | $1,403,532 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 50 | $863,133 | None |
| Injection, golimumab, 1 mg, for intravenous use | 12 | $118,498 | None |
| Return visit (30+ min) | 317 | $69,314 | $99 |
| Short return visit (20+ min) | 361 | $43,476 | $67 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 71 | $33,099 | $63 |
| Injection, denosumab, 1 mg | 22 | $32,469 | None |
| Injection of drug or substance under skin or into muscle | 91 | $10,194 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | $9,587 | $126 |
| New patient visit (45+ min) | 66 | $8,436 | $128 |
| Aspiration and/or injection of fluid from large joint | 30 | $2,897 | $41 |
| Administration of chemotherapy into vein, each additional hour | 14 | $2,198 | $27 |
| New patient visit (30+ min) | 25 | $2,105 | $84 |
| Aspiration and/or injection of fluid from small joint | 15 | $707 | $32 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 52 | $410 | None |
2020: 16 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 52 | $1,257,306 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 40 | $827,492 | None |
| Injection, golimumab, 1 mg, for intravenous use | 25 | $266,331 | None |
| Short return visit (20+ min) | 449 | $53,494 | $59 |
| Return visit (30+ min) | 289 | $41,939 | $84 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 69 | $29,360 | $61 |
| Injection, denosumab, 1 mg | 15 | $24,186 | None |
| Injection of drug or substance under skin or into muscle | 95 | $9,042 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $8,528 | $120 |
| New patient visit (45+ min) | 40 | $5,007 | $125 |
| Aspiration and/or injection of fluid from large joint | 40 | $3,931 | $46 |
| New patient visit (30+ min) | 39 | $3,393 | $87 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,822 | $26 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 86 | $983 | $11 |
| Aspiration and/or injection of fluid from small joint | 17 | $655 | $28 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 59 | $455 | None |
2019: 18 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 57 | $1,191,826 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 53 | $801,565 | None |
| Injection, golimumab, 1 mg, for intravenous use | 38 | $514,400 | None |
| Ustekinumab, for subcutaneous injection, 1 mg | 12 | $478,113 | None |
| Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 16 | $165,384 | $42 |
| Return visit (30+ min) | 440 | $97,875 | $84 |
| Short return visit (20+ min) | 421 | $38,277 | $57 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 93 | $31,812 | $58 |
| New patient visit (45+ min) | 152 | $18,806 | $124 |
| Injection, denosumab, 1 mg | 11 | $16,920 | None |
| Injection of drug or substance under skin or into muscle | 135 | $10,654 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $8,975 | $115 |
| Aspiration and/or injection of fluid from large joint | 62 | $6,622 | $41 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $3,113 | $62 |
| New patient visit (30+ min) | 29 | $2,369 | $82 |
| Administration of chemotherapy into vein, each additional hour | 16 | $1,925 | $25 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 80 | $1,250 | None |
| Aspiration and/or injection of fluid from small joint | 23 | $1,155 | $30 |
2018: 19 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 27 | $477,441 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 29 | $310,898 | None |
| Injection, golimumab, 1 mg, for intravenous use | 20 | $238,159 | None |
| Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 19 | $204,072 | $51 |
| Return visit (30+ min) | 435 | $79,045 | $81 |
| New patient visit (45+ min) | 404 | $49,912 | $124 |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 16 | $25,056 | None |
| Short return visit (20+ min) | 265 | $20,917 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 47 | $13,009 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 22 | $10,587 | $118 |
| Aspiration and/or injection of fluid from large joint | 93 | $10,013 | $43 |
| New patient visit (30+ min) | 116 | $8,963 | $77 |
| Injection of drug or substance under skin or into muscle | 135 | $7,731 | $17 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $7,247 | $64 |
| New patient visit (60+ min) | 39 | $5,813 | $149 |
| Administration of chemotherapy into vein, each additional hour | 22 | $2,296 | $26 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 104 | $1,790 | None |
| Aspiration and/or injection of fluid from small joint | 29 | $1,636 | $34 |
| Injection, methylprednisolone acetate, 80 mg | 21 | $195 | None |
2017: 11 services
| Return visit (30+ min) | 126 | $26,063 | $82 |
| Aspiration and/or injection of fluid from large joint | 60 | $11,760 | $50 |
| New patient visit (45+ min) | 92 | $10,977 | $119 |
| New patient visit (60+ min) | 72 | $10,314 | $143 |
| Short return visit (20+ min) | 73 | $6,081 | $57 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 12 | $5,561 | None |
| Long return visit (40+ min) | 23 | $3,237 | $101 |
| Injection of drug or substance under skin or into muscle | 48 | $3,133 | $21 |
| Injection, methylprednisolone acetate, 80 mg | 53 | $989 | None |
| Injection of trigger points, 1-2 muscles | 12 | $572 | $44 |
| Injection, methylprednisolone acetate, 40 mg | 29 | $223 | None |
2016: 3 services
| New patient visit (60+ min) | 19 | $3,201 | $168 |
| New patient visit (45+ min) | 19 | $2,386 | $126 |
| Return visit (30+ min) | 17 | $1,942 | $84 |
2014: 3 services
| Short return visit (20+ min) | 43 | $1,947 | $34 |
| New patient visit (45+ min) | 16 | $1,777 | $111 |
| Return visit (30+ min) | 19 | $1,669 | $67 |
2013: 6 services
| New patient visit (45+ min) | 69 | $8,746 | $127 |
| Short return visit (20+ min) | 60 | $7,373 | $58 |
| Return visit (30+ min) | 30 | $4,209 | $86 |
| Aspiration and/or injection of fluid from large joint | 27 | $2,434 | $44 |
| New patient visit (30+ min) | 19 | $1,504 | $79 |
| Injection, methylprednisolone acetate, 80 mg | 22 | $225 | None |
Medicaid work
$3,211,176 in 2024
Medicaid paid $3,211,176 for 4,394 billed services this clinician did in 2024, up to 114 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 608 | $1,722,188 |
| Abatacept injection | 460 | $1,373,843 |
| Return visit (30+ min) | 966 | $30,899 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 586 | $30,590 |
| New patient visit (45+ min) | 327 | $20,460 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 528 | $17,502 |
| Short return visit (20+ min) | 388 | $8,530 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 159 | $2,366 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 158 | $2,077 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 78 | $1,255 |
| Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | 124 | $1,113 |
| Arthrocentesis and injection of knee joint | 12 | $353 |
| 2024 | 4,394 | 12 | 114 | $3,211,176 |
| 2023 | 5,670 | 14 | 134 | $4,793,755 |
| 2022 | 5,387 | 11 | 107 | $4,959,603 |
| 2021 | 4,769 | 10 | 94 | $5,203,714 |
| 2020 | 4,250 | 11 | 124 | $4,486,153 |
| 2019 | 3,639 | 12 | 94 | $3,642,115 |
| 2018 | 742 | 6 | 51 | $410,845 |
See the largest Medicaid services in earlier years
2023
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 847 | $2,630,142 |
| Abatacept injection | 639 | $1,977,413 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 699 | $41,386 |
| Return visit (30+ min) | 1,151 | $40,252 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 12 | $29,543 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 644 | $24,944 |
| New patient visit (45+ min) | 285 | $19,704 |
| Short return visit (20+ min) | 666 | $16,215 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 221 | $4,459 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 138 | $3,150 |
| Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | 200 | $2,634 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 119 | $2,260 |
2022
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 842 | $2,802,428 |
| Abatacept injection | 640 | $1,965,820 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 867 | $54,600 |
| Return visit (30+ min) | 982 | $34,071 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 889 | $31,661 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 12 | $31,101 |
| New patient visit (45+ min) | 306 | $19,743 |
| Short return visit (20+ min) | 590 | $13,775 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 198 | $3,730 |
| New patient visit (30+ min) | 32 | $2,003 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 29 | $672 |
2021
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 725 | $3,187,132 |
| Abatacept injection | 495 | $1,849,031 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 26 | $51,416 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 742 | $31,892 |
| Return visit (30+ min) | 909 | $30,315 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 763 | $22,836 |
| New patient visit (45+ min) | 235 | $12,883 |
| Short return visit (20+ min) | 597 | $12,826 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 262 | $4,564 |
| New patient visit (30+ min) | 15 | $820 |
2020
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 674 | $2,906,869 |
| Abatacept injection | 350 | $1,194,611 |
| Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 92 | $286,717 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 538 | $24,916 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 699 | $20,870 |
| Return visit (30+ min) | 585 | $19,633 |
| Short return visit (20+ min) | 908 | $18,942 |
| New patient visit (45+ min) | 91 | $5,923 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 227 | $4,598 |
| New patient visit (30+ min) | 43 | $1,871 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 43 | $1,201 |
2019
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 578 | $2,561,661 |
| Abatacept injection | 234 | $670,015 |
| Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 112 | $314,265 |
| Return visit (30+ min) | 903 | $29,635 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 615 | $18,846 |
| New patient visit (45+ min) | 279 | $18,701 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 392 | $17,061 |
| Short return visit (20+ min) | 398 | $8,682 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 78 | $1,591 |
| New patient visit (30+ min) | 12 | $784 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 19 | $465 |
| Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | 19 | $411 |
2018
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 82 | $380,971 |
| Return visit (30+ min) | 443 | $19,235 |
| New patient visit (45+ min) | 100 | $7,915 |
| Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | 75 | $1,622 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 29 | $769 |
| Short return visit (20+ min) | 13 | $334 |
Drugs they prescribed that Part D paid
$2,187,076
Pharmacies billed $2,187,076 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,875) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
3,568 generic and fewer than 11 brand-name prescriptions · $2,187,076 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enbrel Sureclick | 35 | $265,420 | $7,583 |
| Enbrel | 15 | $201,734 | $13,449 |
| Humira(Cf) | 17 | $188,392 | $11,082 |
| Tremfya | 13 | $165,982 | $12,768 |
| Humira | 11 | $157,988 | $14,363 |
See all 37 drugs
| Enbrel Sureclick | 35 | $265,420 | $7,583 |
| Enbrel | 15 | $201,734 | $13,449 |
| Humira(Cf) | 17 | $188,392 | $11,082 |
| Tremfya | 13 | $165,982 | $12,768 |
| Humira | 11 | $157,988 | $14,363 |
| Orencia | 21 | $155,320 | $7,396 |
| Otezla | 31 | $140,323 | $4,527 |
| Xeljanz | 18 | $117,806 | $6,545 |
| Cosentyx Sensoready (2 Pens) | 11 | $80,363 | $7,306 |
| Actemra | 13 | $51,809 | $3,985 |
| Hydroxychloroquine Sulfate | 828 | $33,816 | $41 |
| Methotrexate | 567 | $22,988 | $41 |
| Leflunomide | 105 | $10,169 | $97 |
| Prednisone | 1,003 | $7,367 | $7 |
| Colchicine | 62 | $4,973 | $80 |
| Mycophenolate Mofetil | 30 | $4,972 | $166 |
| Celecoxib | 83 | $4,919 | $59 |
| Gabapentin | 188 | $2,981 | $16 |
| Allopurinol | 83 | $2,691 | $32 |
| Diclofenac | 69 | $2,646 | $38 |
| Pilocarpine | 22 | $2,101 | $95 |
| Clobetasol Propionate | 55 | $2,047 | $37 |
| Cevimeline | 16 | $1,493 | $93 |
| Sulfasalazine | 53 | $1,407 | $27 |
| Leucovorin | 33 | $1,206 | $37 |
| Febuxostat | 14 | $779 | $56 |
| Amitriptyline | 60 | $571 | $10 |
| Azathioprine | 12 | $458 | $38 |
| Omeprazole | 35 | $456 | $13 |
| Folic Acid | 53 | $448 | $8 |
| Alendronate | 32 | $388 | $12 |
| Meloxicam | 38 | $354 | $9 |
| Ibuprofen | 37 | $293 | $8 |
| Nabumetone | 13 | $247 | $19 |
| Methylprednisolone | 11 | $196 | $18 |
| Naproxen | 24 | $162 | $7 |
| Cyclobenzaprine | 20 | $140 | $7 |
Year by year
| 2024 | 3,875 | 554 | 0% (0) | None | $2,187,076 |
| 2023 | 3,796 | 545 | 0% (0) | None | $2,308,341 |
| 2022 | 3,689 | 534 | None | None | $1,921,424 |
| 2021 | 3,605 | 506 | None | None | $1,568,861 |
| 2020 | 3,344 | 536 | None | None | $1,440,990 |
| 2019 | 3,954 | 654 | 3% (113) | 10% | $1,687,748 |
| 2018 | 4,912 | 706 | 4% (204) | 12% | $1,806,640 |
| 2017 | 1,697 | 192 | 1% (22) | 10% | $306,359 |
| 2016 | 75 | 20 | None | 20% | $9,935 |
| 2015 | 70 | 13 | 0% (0) | 30% | $6,262 |
| 2014 | 1,094 | 131 | 1% (15) | None | $81,402 |
| 2013 | 930 | 144 | 2% (21) | None | $42,384 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Enbrel | 23 | $300,436 | $13,062 |
| Humira(Cf) | 26 | $253,805 | $9,762 |
| Otezla | 44 | $231,430 | $5,260 |
| Tremfya | 14 | $203,536 | $14,538 |
| Humira | 17 | $167,686 | $9,864 |
| Enbrel Sureclick | 23 | $162,288 | $7,056 |
| Orencia | 20 | $150,336 | $7,517 |
| Cosentyx Sensoready (2 Pens) | 15 | $122,119 | $8,141 |
| Xeljanz | 11 | $66,005 | $6,000 |
| Actemra | 13 | $63,462 | $4,882 |
| Hydroxychloroquine Sulfate | 778 | $51,475 | $66 |
| Methotrexate | 493 | $27,617 | $56 |
| Celecoxib | 103 | $9,562 | $93 |
| Prednisone | 924 | $9,451 | $10 |
| Diclofenac | 171 | $9,052 | $53 |
| Leflunomide | 95 | $8,480 | $89 |
| Clobetasol Propionate | 47 | $5,848 | $124 |
| Cevimeline | 14 | $4,852 | $347 |
| Colchicine | 69 | $4,665 | $68 |
| Gabapentin | 188 | $4,133 | $22 |
| Mycophenolate Mofetil | 23 | $3,754 | $163 |
| Sulfasalazine | 83 | $2,720 | $33 |
| Pilocarpine | 20 | $2,334 | $117 |
| Meloxicam | 71 | $1,091 | $15 |
| Allopurinol | 72 | $1,065 | $15 |
| Febuxostat | 12 | $892 | $74 |
| Leucovorin | 31 | $839 | $27 |
| Amitriptyline | 59 | $826 | $14 |
| Omeprazole | 33 | $552 | $17 |
| Naproxen | 38 | $456 | $12 |
| Ibuprofen | 38 | $422 | $11 |
| Alendronate | 34 | $368 | $11 |
| Folic Acid | 48 | $229 | $5 |
| Cyclobenzaprine | 19 | $137 | $7 |
2022: 33 drugs
| Enbrel | 26 | $357,059 | $13,733 |
| Humira(Cf) | 26 | $292,978 | $11,268 |
| Otezla | 37 | $219,228 | $5,925 |
| Humira | 12 | $150,823 | $12,569 |
| Orencia | 16 | $97,265 | $6,079 |
| Enbrel Sureclick | 11 | $75,112 | $6,828 |
| Xeljanz | 12 | $67,958 | $5,663 |
| Hydroxychloroquine Sulfate | 766 | $56,142 | $73 |
| Actemra | 11 | $50,660 | $4,605 |
| Methotrexate | 503 | $31,669 | $63 |
| Leflunomide | 106 | $15,901 | $150 |
| Prednisone | 973 | $11,207 | $12 |
| Celecoxib | 109 | $10,555 | $97 |
| Colchicine | 52 | $7,115 | $137 |
| Diclofenac | 105 | $4,267 | $41 |
| Gabapentin | 196 | $4,031 | $21 |
| Cevimeline | 11 | $3,824 | $348 |
| Mycophenolate Mofetil | 11 | $2,616 | $238 |
| Sulfasalazine | 78 | $2,161 | $28 |
| Clobetasol Propionate | 35 | $1,916 | $55 |
| Pilocarpine | 14 | $1,801 | $129 |
| Amitriptyline | 96 | $1,138 | $12 |
| Allopurinol | 67 | $1,088 | $16 |
| Meloxicam | 69 | $712 | $10 |
| Omeprazole | 35 | $613 | $18 |
| Nifedipine Er | 12 | $576 | $48 |
| Ibuprofen | 30 | $427 | $14 |
| Leucovorin | 18 | $426 | $24 |
| Methylprednisolone | 13 | $390 | $30 |
| Folic Acid | 51 | $361 | $7 |
| Nabumetone | 14 | $347 | $25 |
| Naproxen | 34 | $335 | $10 |
| Alendronate | 19 | $220 | $12 |
2021: 29 drugs
| Enbrel | 27 | $328,459 | $12,165 |
| Enbrel Sureclick | 27 | $180,574 | $6,688 |
| Humira(Cf) | 21 | $177,089 | $8,433 |
| Otezla | 24 | $131,604 | $5,484 |
| Orencia | 13 | $67,097 | $5,161 |
| Hydroxychloroquine Sulfate | 721 | $52,779 | $73 |
| Methotrexate | 555 | $33,238 | $60 |
| Leflunomide | 123 | $14,858 | $121 |
| Colchicine | 74 | $12,925 | $175 |
| Prednisone | 1,014 | $12,173 | $12 |
| Celecoxib | 102 | $6,897 | $68 |
| Mycophenolate Mofetil | 21 | $3,175 | $151 |
| Gabapentin | 139 | $2,684 | $19 |
| Pilocarpine | 18 | $2,607 | $145 |
| Diclofenac | 38 | $2,069 | $54 |
| Sulfasalazine | 46 | $1,468 | $32 |
| Allopurinol | 71 | $1,286 | $18 |
| Clobetasol Propionate | 23 | $1,239 | $54 |
| Amitriptyline | 58 | $939 | $16 |
| Meloxicam | 103 | $938 | $9 |
| Leucovorin | 25 | $917 | $37 |
| Duloxetine | 13 | $534 | $41 |
| Omeprazole | 24 | $472 | $20 |
| Nabumetone | 12 | $453 | $38 |
| Ibuprofen | 24 | $375 | $16 |
| Alendronate | 20 | $299 | $15 |
| Methotrexate | 13 | $291 | $22 |
| Folic Acid | 53 | $276 | $5 |
| Naproxen | 32 | $182 | $6 |
2020: 32 drugs
| Enbrel | 25 | $298,400 | $11,936 |
| Enbrel Sureclick | 25 | $184,035 | $7,361 |
| Humira(Cf) | 11 | $168,515 | $15,320 |
| Simponi | 12 | $145,927 | $12,161 |
| Humira | 22 | $123,489 | $5,613 |
| Otezla | 13 | $89,727 | $6,902 |
| Xeljanz | 17 | $80,705 | $4,747 |
| Hydroxychloroquine Sulfate | 720 | $72,019 | $100 |
| Methotrexate | 536 | $38,994 | $73 |
| Colchicine | 60 | $17,934 | $299 |
| Leflunomide | 69 | $11,623 | $168 |
| Prednisone | 901 | $11,486 | $13 |
| Colcrys | 16 | $8,168 | $511 |
| Celecoxib | 79 | $5,899 | $75 |
| Febuxostat | 12 | $5,645 | $470 |
| Mycophenolate Mofetil | 31 | $5,444 | $176 |
| Diclofenac | 76 | $4,059 | $53 |
| Gabapentin | 115 | $3,098 | $27 |
| Cevimeline | 12 | $1,995 | $166 |
| Allopurinol | 74 | $1,499 | $20 |
| Clobetasol Propionate | 18 | $1,322 | $73 |
| Sulfasalazine | 30 | $1,200 | $40 |
| Meloxicam | 113 | $996 | $9 |
| Amitriptyline | 51 | $908 | $18 |
| Leucovorin | 22 | $692 | $31 |
| Omeprazole | 25 | $502 | $20 |
| Ibuprofen | 30 | $420 | $14 |
| Nabumetone | 11 | $364 | $33 |
| Methotrexate | 15 | $350 | $23 |
| Cyclobenzaprine | 13 | $329 | $25 |
| Naproxen | 29 | $322 | $11 |
| Alendronate | 17 | $199 | $12 |
2019: 35 drugs
| Humira | 50 | $297,161 | $5,943 |
| Enbrel Sureclick | 42 | $294,655 | $7,016 |
| Simponi | 20 | $156,137 | $7,807 |
| Humira(Cf) | 14 | $132,472 | $9,462 |
| Hydroxychloroquine Sulfate | 695 | $93,691 | $135 |
| Methotrexate | 685 | $57,808 | $84 |
| Colchicine | 48 | $19,156 | $399 |
| Leflunomide | 68 | $18,581 | $273 |
| Prednisone | 1,044 | $14,319 | $14 |
| Celecoxib | 90 | $6,349 | $71 |
| Diclofenac | 100 | $6,207 | $62 |
| Colcrys | 12 | $5,730 | $477 |
| Mycophenolate Mofetil | 21 | $4,274 | $204 |
| Gabapentin | 137 | $4,174 | $30 |
| Pilocarpine | 12 | $3,305 | $275 |
| Voltaren | 22 | $3,036 | $138 |
| Clobetasol Propionate | 23 | $2,772 | $121 |
| Sulfasalazine | 39 | $2,261 | $58 |
| Allopurinol | 74 | $1,957 | $26 |
| Meloxicam | 151 | $1,514 | $10 |
| Cevimeline | 13 | $1,384 | $106 |
| Hydrocodone-Acetaminophen | 49 | $896 | $18 |
| Cyclobenzaprine | 37 | $718 | $19 |
| Amitriptyline | 53 | $631 | $12 |
| Naproxen | 49 | $627 | $13 |
| Methotrexate | 22 | $580 | $26 |
| Nabumetone | 12 | $486 | $41 |
| Ibuprofen | 37 | $466 | $13 |
| Tramadol | 47 | $421 | $9 |
| Leucovorin | 13 | $324 | $25 |
| Omeprazole | 23 | $291 | $13 |
| Methylprednisolone | 13 | $264 | $20 |
| Alendronate | 17 | $175 | $10 |
| Acetaminophen-Codeine | 17 | $137 | $8 |
| Insulin | 11 | $81 | $7 |
2018: 36 drugs
| Humira | 108 | $599,001 | $5,546 |
| Enbrel Sureclick | 34 | $277,415 | $8,159 |
| Humira | 35 | $215,358 | $6,153 |
| Simponi | 18 | $110,980 | $6,166 |
| Enbrel | 14 | $109,191 | $7,799 |
| Hydroxychloroquine Sulfate | 812 | $87,627 | $108 |
| Xeljanz Xr | 18 | $74,072 | $4,115 |
| Methotrexate | 831 | $62,632 | $75 |
| Leflunomide | 71 | $19,018 | $268 |
| Lyrica | 35 | $13,881 | $397 |
| Prednisone | 1,246 | $12,392 | $10 |
| Celecoxib | 92 | $11,559 | $126 |
| Colcrys | 14 | $7,035 | $503 |
| Diclofenac | 86 | $5,996 | $70 |
| Colchicine | 18 | $5,652 | $314 |
| Gabapentin | 246 | $3,494 | $14 |
| Hydrocodone-Acetaminophen | 126 | $3,206 | $25 |
| Pilocarpine | 11 | $2,942 | $267 |
| Voltaren | 36 | $2,792 | $78 |
| Mycophenolate Mofetil | 17 | $2,078 | $122 |
| Sulfasalazine | 76 | $2,045 | $27 |
| Cevimeline | 13 | $2,019 | $155 |
| Meloxicam | 251 | $1,785 | $7 |
| Naproxen | 105 | $1,010 | $10 |
| Allopurinol | 60 | $1,000 | $17 |
| Amitriptyline | 73 | $939 | $13 |
| Cyclobenzaprine | 55 | $787 | $14 |
| Omeprazole | 60 | $711 | $12 |
| Methotrexate | 30 | $645 | $21 |
| Duloxetine | 20 | $586 | $29 |
| Tramadol | 67 | $523 | $8 |
| Nifedipine Er | 21 | $505 | $24 |
| Nabumetone | 17 | $483 | $28 |
| Ibuprofen | 31 | $255 | $8 |
| Acetaminophen-Codeine | 11 | $100 | $9 |
| Insulin | 14 | $69 | $5 |
2017: 14 drugs
| Humira | 33 | $176,096 | $5,336 |
| Hydroxychloroquine Sulfate | 438 | $35,291 | $81 |
| Methotrexate | 255 | $15,542 | $61 |
| Celecoxib | 38 | $2,728 | $72 |
| Prednisone | 436 | $2,560 | $6 |
| Diclofenac | 23 | $1,759 | $76 |
| Sulfasalazine | 42 | $1,181 | $28 |
| Voltaren | 17 | $889 | $52 |
| Amitriptyline | 63 | $689 | $11 |
| Gabapentin | 88 | $634 | $7 |
| Cyclobenzaprine | 33 | $373 | $11 |
| Omeprazole | 41 | $308 | $8 |
| Naproxen | 30 | $170 | $6 |
| Meloxicam | 35 | $116 | $3 |
2016: 2 drugs
| Hydroxychloroquine Sulfate | 13 | $957 | $74 |
| Prednisone | 15 | $105 | $7 |
2015: 3 drugs
| Tamsulosin | 12 | $277 | $23 |
| Levothyroxine | 12 | $206 | $17 |
| Lisinopril | 12 | $98 | $8 |
2014: 15 drugs
| Methotrexate | 202 | $15,247 | $75 |
| Hydroxychloroquine Sulfate | 226 | $5,376 | $24 |
| Lyrica | 20 | $5,218 | $261 |
| Prednisone | 326 | $3,180 | $10 |
| Colcrys | 11 | $1,617 | $147 |
| Voltaren | 30 | $1,603 | $53 |
| Sulfasalazine | 47 | $1,065 | $23 |
| Leflunomide | 12 | $607 | $51 |
| Sulfazine | 14 | $343 | $24 |
| Levothyroxine | 11 | $163 | $15 |
| Gabapentin | 20 | $150 | $8 |
| Tamsulosin | 11 | $148 | $13 |
| Amitriptyline | 33 | $146 | $4 |
| Cyclobenzaprine | 12 | $106 | $9 |
| Lisinopril | 11 | $82 | $7 |
2013: 10 drugs
| Methotrexate | 147 | $10,837 | $74 |
| Hydroxychloroquine Sulfate | 190 | $2,885 | $15 |
| Voltaren | 58 | $2,581 | $45 |
| Prednisone | 296 | $1,803 | $6 |
| Sulfasalazine | 31 | $503 | $16 |
| Leflunomide | 16 | $425 | $27 |
| Sulfazine | 12 | $186 | $16 |
| Cyclobenzaprine | 23 | $160 | $7 |
| Levothyroxine | 12 | $128 | $11 |
| Lisinopril | 12 | $88 | $7 |
Money from drug and device companies
$5,114 in 2025
| 2025 | 23 | 213 | None | $5,114 |
| 2024 | 21 | 155 | None | $3,256 |
| 2023 | 22 | 141 | None | $2,769 |
| 2022 | 15 | 146 | None | $2,550 |
| 2021 | 8 | 32 | None | $627 |
| 2020 | 9 | 24 | $220 | $580 |
| 2019 | 17 | 161 | $2,693 | $4,832 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Krystexxa | $1,375 | 68 payments
|
| Janssen Biotech | Tremfya | $790 | 23 payments
|
| Novartis Pharmaceuticals | Cosentyx | $419 | 18 payments
|
| Abbvie | Skyrizi | $394 | 20 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $341 | 13 payments
|
| Genzyme | Kevzara | $281 | 2 payments
|
See all 213 published payments
| Mallinckrodt Hospital Products | Meals · 2025-12-19 | Acthar | $34 |
| Amgen | Meals · 2025-12-19 | Otezla | $32 |
| Amgen | Meals · 2025-12-17 | Tavneos | $7 |
| Janssen Biotech | Meals · 2025-12-16 | Tremfya | $15 |
| Ucb | Meals · 2025-12-16 | Bimzelx | $19 |
| Janssen Pharmaceuticals | Education · 2025-12-15 | Tremfya | $13 |
| Amgen | Meals · 2025-12-15 | Krystexxa | $25 |
| Genentech USA | Meals · 2025-12-12 | Gazyva | $29 |
| Abbvie | Meals · 2025-12-06 | Skyrizi | $17 |
| Amgen | Meals · 2025-12-05 | Otezla | $12 |
| Organon | Meals · 2025-12-05 | Hadlima | $29 |
| Ucb | Meals · 2025-12-04 | Bimzelx | $25 |
| Novartis Pharmaceuticals | Meals · 2025-12-03 | Cosentyx | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-02 | Saphnelo | $25 |
| GlaxoSmithKline | Meals · 2025-12-01 | Benlysta | $33 |
| GlaxoSmithKline | Meals · 2025-11-25 | Benlysta | $18 |
| Alexion Pharmaceuticals | Meals · 2025-11-21 | Strensiq | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-21 | Saphnelo | $33 |
| Abbvie | Meals · 2025-11-20 | Rinvoq | $13 |
| Ucb | Meals · 2025-11-18 | Bimzelx | $18 |
| Amgen | Meals · 2025-11-18 | Krystexxa | $11 |
| Abbvie | Meals · 2025-11-17 | Rinvoq | $35 |
| Amgen | Meals · 2025-11-14 | Otezla | $13 |
| Fresenius Kabi USA | Meals · 2025-11-14 | None | $34 |
| Organon | Meals · 2025-11-13 | None | $34 |
| Genentech USA | Meals · 2025-11-12 | Gazyva | $25 |
| Genzyme | Meals · 2025-11-07 | Kevzara | $144 |
| Genzyme | Meals · 2025-11-06 | Kevzara | $136 |
| Ucb | Meals · 2025-11-04 | Bimzelx | $16 |
| Amgen | Meals · 2025-11-03 | Krystexxa | $17 |
| Amgen | Meals · 2025-10-31 | Krystexxa | $4 |
| Novartis Pharmaceuticals | Meals · 2025-10-30 | Cosentyx | $35 |
| Janssen Biotech | Meals · 2025-10-29 | Tremfya | $4 |
| Janssen Biotech | Meals · 2025-10-29 | Tremfya | $32 |
| Amgen | Meals · 2025-10-29 | Tavneos | $9 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-28 | Saphnelo | $32 |
| Abbvie | Meals · 2025-10-24 | Rinvoq | $7 |
| Amgen | Meals · 2025-10-24 | Krystexxa | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Saphnelo | $25 |
| Amgen | Meals · 2025-10-23 | Krystexxa | $9 |
| Octapharma USA | Meals · 2025-10-22 | Octagam Immune Globulin (Human) | $18 |
| Janssen Biotech | Meals · 2025-10-20 | Tremfya | $33 |
| Janssen Biotech | Meals · 2025-10-20 | Tremfya | $2 |
| Amgen | Meals · 2025-10-17 | Evenity | $25 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | None | $31 |
| Novartis Pharmaceuticals | Meals · 2025-10-14 | Cosentyx | $29 |
| Organon | Meals · 2025-10-10 | Hadlima | $26 |
| Abbvie | Meals · 2025-10-09 | Skyrizi | $27 |
| Janssen Biotech | Meals · 2025-10-03 | Tremfya | $6 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-03 | Orencia | $28 |
| GlaxoSmithKline | Meals · 2025-10-02 | Benlysta | $4 |
| GlaxoSmithKline | Meals · 2025-10-02 | Benlysta | $27 |
| Abbvie | Meals · 2025-09-27 | Skyrizi | $11 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-27 | Saphnelo | $31 |
| Abbvie | Meals · 2025-09-26 | Rinvoq | $7 |
| Mallinckrodt Hospital Products | Meals · 2025-09-26 | Acthar | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-25 | Cosentyx | $7 |
| Amgen | Meals · 2025-09-19 | Krystexxa | $28 |
| Amgen | Meals · 2025-09-16 | Otezla | $20 |
| Abbvie | Meals · 2025-09-12 | Skyrizi | $31 |
| Alexion Pharmaceuticals | Meals · 2025-09-11 | Strensiq | $22 |
| Amgen | Meals · 2025-09-10 | Tavneos | $14 |
| Janssen Biotech | Meals · 2025-09-09 | Tremfya | $38 |
| Janssen Biotech | Meals · 2025-09-05 | Tremfya | $42 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-05 | Saphnelo | $11 |
| Novartis Pharmaceuticals | Meals · 2025-09-04 | Cosentyx | $29 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Cosentyx | $12 |
| Abbvie | Meals · 2025-08-28 | Skyrizi | $9 |
| Amgen | Meals · 2025-08-28 | Krystexxa | $9 |
| Amgen | Meals · 2025-08-28 | None | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-27 | Orencia | $19 |
| Amgen | Meals · 2025-08-22 | Otezla | $34 |
| GlaxoSmithKline | Meals · 2025-08-21 | Benlysta | $33 |
| Amgen | Meals · 2025-08-18 | Uplizna | $22 |
| Abbvie | Meals · 2025-08-15 | Rinvoq | $33 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | Cosentyx | $11 |
| Abbvie | Meals · 2025-08-14 | Skyrizi | $26 |
| Abbvie | Meals · 2025-08-08 | Rinvoq | $9 |
| Genentech USA | Meals · 2025-08-07 | Actemra | $32 |
| Ucb | Meals · 2025-08-07 | Bimzelx | $9 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-06 | Orencia | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-06 | Orencia | $1 |
| Novartis Pharmaceuticals | Meals · 2025-08-05 | Cosentyx | $21 |
| Organon | Meals · 2025-08-01 | Hadlima | $28 |
| Janssen Biotech | Meals · 2025-07-31 | Tremfya | $27 |
| Amgen | Meals · 2025-07-31 | Krystexxa | $10 |
| Amgen | Meals · 2025-07-31 | Uplizna | $13 |
| Aurinia Pharma U.S. | Meals · 2025-07-29 | Lupkynis | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-28 | Orencia | $25 |
| TerSera Therapeutics | Meals · 2025-07-24 | Quzyttir | $20 |
| Amgen | Meals · 2025-07-18 | Uplizna | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Saphnelo | $33 |
| GlaxoSmithKline | Meals · 2025-07-15 | Benlysta | $17 |
| Novartis Pharmaceuticals | Meals · 2025-07-11 | Cosentyx | $35 |
| Mallinckrodt Hospital Products | Meals · 2025-07-10 | Acthar | $27 |
| Janssen Biotech | Meals · 2025-07-09 | Tremfya | $25 |
| Pfizer | Meals · 2025-07-08 | Xeljanz | $17 |
| Abbvie | Meals · 2025-06-27 | Skyrizi | $24 |
| Amgen | Meals · 2025-06-26 | Uplizna | $12 |
| Amgen | Meals · 2025-06-26 | Krystexxa | $28 |
| Amgen | Meals · 2025-06-25 | Evenity | $24 |
| Novartis Pharmaceuticals | Meals · 2025-06-24 | Cosentyx | $18 |
| Organon | Meals · 2025-06-20 | Hadlima | $29 |
| Janssen Biotech | Meals · 2025-06-19 | Tremfya | $45 |
| Amgen | Meals · 2025-06-19 | Krystexxa | $7 |
| Amgen | Meals · 2025-06-18 | Otezla | $21 |
| Ucb | Meals · 2025-06-16 | Bimzelx | $34 |
| Abbvie | Meals · 2025-06-13 | Rinvoq | $33 |
| Novartis Pharmaceuticals | Meals · 2025-06-12 | Cosentyx | $32 |
| Amgen | Meals · 2025-06-12 | Tavneos | $10 |
| Organon | Meals · 2025-06-11 | Renflexis | $21 |
| Amgen | Meals · 2025-06-10 | Uplizna | $10 |
| Janssen Biotech | Meals · 2025-06-09 | Tremfya | $30 |
| Amgen | Meals · 2025-06-06 | Evenity | $40 |
| Pfizer | Meals · 2025-06-05 | Xeljanz | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-03 | Saphnelo | $19 |
| Janssen Biotech | Meals · 2025-05-31 | Tremfya | $37 |
| Novartis Pharmaceuticals | Meals · 2025-05-29 | Cosentyx | $7 |
| Amgen | Meals · 2025-05-29 | Otezla | $26 |
| GlaxoSmithKline | Meals · 2025-05-28 | Benlysta | $18 |
| Genentech USA | Meals · 2025-05-22 | Actemra | $27 |
| Lilly USA | Meals · 2025-05-20 | Taltz | $17 |
| Amgen | Meals · 2025-05-16 | Krystexxa | $27 |
| Amgen | Meals · 2025-05-14 | Krystexxa | $125 |
| Amgen | Meals · 2025-05-14 | Krystexxa | $125 |
| Pfizer | Meals · 2025-05-13 | Xeljanz | $23 |
| Amgen | Meals · 2025-05-12 | Krystexxa | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-09 | Saphnelo | $31 |
| Abbvie | Meals · 2025-05-08 | Rinvoq | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-02 | Orencia | $6 |
| Abbvie | Meals · 2025-05-02 | Skyrizi | $27 |
| Alexion Pharmaceuticals | Meals · 2025-05-01 | Strensiq | $31 |
| Amgen | Meals · 2025-05-01 | Uplizna | $10 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $38 |
| GlaxoSmithKline | Meals · 2025-04-28 | Benlysta | $6 |
| Novartis Pharmaceuticals | Meals · 2025-04-28 | Cosentyx | $27 |
| Janssen Biotech | Meals · 2025-04-25 | Tremfya | $32 |
| TerSera Therapeutics | Meals · 2025-04-24 | Quzyttir | $23 |
| Amgen | Meals · 2025-04-22 | Uplizna | $22 |
| Amgen | Meals · 2025-04-21 | Krystexxa | $26 |
| Mallinckrodt Hospital Products | Meals · 2025-04-18 | Acthar | $31 |
| Amgen | Meals · 2025-04-18 | Krystexxa | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-17 | Saphnelo | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-16 | Orencia | $20 |
| Amgen | Meals · 2025-04-16 | Tavneos | $9 |
| Amgen | Meals · 2025-04-15 | Krystexxa | $12 |
| Fresenius Kabi USA | Meals · 2025-04-15 | None | $15 |
| Organon | Meals · 2025-04-11 | Nexplanon | $26 |
| Amgen | Meals · 2025-04-10 | Krystexxa | $29 |
| Amgen | Meals · 2025-04-09 | Uplizna | $14 |
| GlaxoSmithKline | Meals · 2025-04-08 | Benlysta | $28 |
| Ucb | Meals · 2025-04-05 | Cimzia | $16 |
| Genentech USA | Meals · 2025-04-04 | Actemra | $35 |
| GlaxoSmithKline | Meals · 2025-04-03 | Benlysta | $28 |
| Novartis Pharmaceuticals | Meals · 2025-04-02 | Cosentyx | $15 |
| Novartis Pharmaceuticals | Meals · 2025-04-01 | Cosentyx | $33 |
| Amgen | Meals · 2025-04-01 | Uplizna | $4 |
| Amgen | Meals · 2025-04-01 | Uplizna | $29 |
| Janssen Biotech | Education · 2025-03-28 | Tremfya | $99 |
| Janssen Biotech | Meals · 2025-03-28 | Tremfya | $29 |
| Amgen | Meals · 2025-03-27 | None | $12 |
| Amgen | Meals · 2025-03-27 | Uplizna | $19 |
| Amgen | Meals · 2025-03-27 | Evenity | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-25 | Saphnelo | $27 |
| Amgen | Meals · 2025-03-21 | Krystexxa | $24 |
| Amgen | Meals · 2025-03-20 | Krystexxa | $15 |
| Amgen | Meals · 2025-03-20 | Otezla | $25 |
| Ucb | Meals · 2025-03-18 | Bimzelx | $20 |
| Janssen Biotech | Meals · 2025-03-17 | Tremfya | $8 |
| Amgen | Meals · 2025-03-14 | Krystexxa | $7 |
| Amgen | Meals · 2025-03-13 | None | $19 |
| Amgen | Meals · 2025-03-13 | Uplizna | $22 |
| Janssen Biotech | Meals · 2025-03-11 | Tremfya | $150 |
| Abbvie | Meals · 2025-03-06 | Skyrizi | $24 |
| Amgen | Meals · 2025-03-06 | None | $10 |
| Janssen Biotech | Meals · 2025-03-04 | Tremfya | $22 |
| Genentech USA | Meals · 2025-02-28 | Actemra | $19 |
| Amgen | Meals · 2025-02-28 | Tepezza | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-26 | Ofev | $15 |
| Amgen | Meals · 2025-02-26 | None | $12 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-25 | Orencia | $16 |
| Organon | Meals · 2025-02-21 | Hadlima | $24 |
| Amgen | Meals · 2025-02-20 | None | $11 |
| Amgen | Meals · 2025-02-20 | Krystexxa | $24 |
| Pfizer | Meals · 2025-02-18 | Xeljanz | $19 |
| Pfizer | Meals · 2025-02-15 | Xeljanz | $29 |
| Novartis Pharmaceuticals | Meals · 2025-02-13 | Cosentyx | $26 |
| Amgen | Meals · 2025-02-12 | Tavneos | $12 |
| Janssen Biotech | Meals · 2025-02-07 | Tremfya | $40 |
| Abbvie | Meals · 2025-02-06 | Skyrizi | $20 |
| Amgen | Meals · 2025-02-06 | Krystexxa | $13 |
| Lilly USA | Meals · 2025-02-05 | Taltz | $14 |
| Amgen | Meals · 2025-02-04 | None | $11 |
| Amgen | Meals · 2025-02-04 | Krystexxa | $17 |
| GlaxoSmithKline | Meals · 2025-01-30 | Benlysta | $29 |
| Amgen | Meals · 2025-01-30 | Krystexxa | $12 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-29 | Saphnelo | $30 |
| Amgen | Meals · 2025-01-29 | Otezla | $22 |
| Amgen | Meals · 2025-01-24 | Krystexxa | $10 |
| Abbvie | Meals · 2025-01-23 | Skyrizi | $7 |
| Amgen | Meals · 2025-01-23 | None | $3 |
| Amgen | Meals · 2025-01-23 | None | $17 |
| Novartis Pharmaceuticals | Meals · 2025-01-21 | Cosentyx | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Orencia | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Orencia | $2 |
| Ucb | Meals · 2025-01-17 | Cimzia | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-16 | Saphnelo | $26 |
| Biocon Biologics | Meals · 2025-01-14 | Hulio | $22 |
| Fidia Pharma USA | Meals · 2025-01-10 | Hymovis | $31 |
| Abbvie | Meals · 2025-01-09 | Skyrizi | $24 |
| Pfizer | Meals · 2025-01-08 | Xeljanz | $23 |
| Janssen Biotech | Meals · 2025-01-06 | Tremfya | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,256
| Amgen | Krystexxa | $727 | 45 payments
|
| Janssen Biotech | Tremfya | $646 | 21 payments
|
| Novartis Pharmaceuticals | Cosentyx | $262 | 11 payments
|
| Pfizer | Xeljanz | $235 | 12 payments
|
| Ucb | Cimzia | $223 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $167 | 8 payments
|
| Abbvie | Skyrizi | $154 | 7 payments
|
| Fresenius Kabi USA | Idacio | $149 | 7 payments
|
| Organon | Hadlima | $109 | 4 payments
|
| Lilly USA | Taltz | $100 | 4 payments
|
| GlaxoSmithKline | Benlysta | $99 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $74 | 3 payments
|
| Genentech USA | Actemra | $68 | 3 payments
|
| Aurinia Pharma U.S. | Lupkynis | $63 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $44 | 2 payments
|
| Hospira | Octagam Immune Globulin (Human) | $31 | 2 payments
|
| Fidia Pharma USA | Hymovis | $26 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $24 | 1 payment
|
| Sandoz | Hyrimoz | $22 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $19 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $16 | 1 payment
|
2023: $2,769
| Janssen Biotech | Tremfya | $343 | 20 payments
|
| Amgen | Enbrel | $328 | 18 payments
|
| Ucb | Cimzia | $257 | 12 payments
|
| Horizon Therapeutics plc | Krystexxa | $211 | 18 payments
|
| GlaxoSmithKline | Benlysta | $208 | 11 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $190 | 7 payments
|
| Novartis Pharmaceuticals | Cosentyx | $189 | 9 payments
|
| Lilly USA | Taltz | $177 | 6 payments
|
| AbbVie | Rinvoq | $162 | 9 payments
|
| Fresenius Kabi USA | Idacio | $109 | 5 payments
|
| Pfizer | Xeljanz | $103 | 5 payments
|
| Aurinia Pharma U.S. | Lupkynis | $74 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $72 | 3 payments
|
| Fidia Pharma USA | Hymovis | $58 | 2 payments
|
| Genzyme | Kevzara | $54 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $50 | 2 payments
|
| Organon | Renflexis | $48 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $36 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $34 | 1 payment
|
| Octapharma USA | Panzyga | $26 | 1 payment
|
| Sandoz | Hyrimoz | $20 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $19 | 1 payment
|
2022: $2,550
| Horizon Therapeutics plc | Krystexxa | $417 | 30 payments
|
| Amgen | Enbrel | $345 | 21 payments
|
| Janssen Biotech | Tremfya | $320 | 18 payments
|
| Novartis Pharmaceuticals | Cosentyx | $227 | 14 payments
|
| Ucb | Cimzia | $211 | 13 payments
|
| Abbvie | Rinvoq | $193 | 11 payments
|
| GlaxoSmithKline | Benlysta | $175 | 9 payments
|
| Lilly USA | Taltz | $142 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $128 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $97 | 6 payments
|
| Aurinia Pharma U.S. | Lupkynis | $87 | 5 payments
|
| Janssen Scientific Affairs | Tremfya | $77 | 1 payment
|
| Pfizer | Xeljanz | $75 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $34 | 2 payments
|
| Fidia Pharma USA | Hymovis | $21 | 1 payment
|
2021: $627
| Horizon Therapeutics plc | Krystexxa | $209 | 13 payments
|
| GlaxoSmithKline | Benlysta | $139 | 4 payments
|
| Amgen | Enbrel | $65 | 4 payments
|
| AbbVie | Rinvoq | $64 | 3 payments
|
| Janssen Biotech | Tremfya | $46 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $43 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $42 | 2 payments
|
| Pfizer | Xeljanz | $18 | 1 payment
|
2020: $580
| Horizon Therapeutics plc | Krystexxa | $257 | 3 payments
|
| Amgen | Enbrel | $128 | 10 payments
|
| Janssen Biotech | Simponi Aria | $57 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $55 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $19 | 1 payment
|
| GlaxoSmithKline | Benlysta | $18 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
| Pfizer | Inflectra | $15 | 1 payment
|
| Genzyme | Kevzara | $15 | 1 payment
|
2019: $4,832
| AbbVie | Humira | $1,956 | 15 payments
|
| Janssen Biotech | Stelara | $770 | 20 payments
|
| Amgen | Enbrel | $476 | 31 payments
|
| Celgene | Otezla | $419 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $184 | 13 payments
|
| Medexus Pharma | Rasuvo | $178 | 20 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $156 | 19 payments
|
| Horizon Therapeutics plc | Krystexxa | $155 | 14 payments
|
| Oxford Immunotec USA | Tspot Tb Test | $146 | 1 payment
|
| Pfizer | Xeljanz | $84 | 6 payments
|
| Genentech USA | Rituxan | $76 | 5 payments
|
| Alexion Pharmaceuticals | Strensiq | $65 | 3 payments
|
| Mallinckrodt Enterprises | Acthar | $49 | 2 payments
|
| Ucb | Cimzia | $40 | 3 payments
|
| Lilly USA | Taltz | $36 | 2 payments
|
| GlaxoSmithKline | Benlysta | $26 | 2 payments
|
| Genzyme | Kevzara | $17 | 1 payment
|
Checkups this office reported
7 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Daily function assessedPatients whose ability to manage daily activities was assessed | 100%That's most of the people this applied to. | 37 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 100%That's most of the people this applied to. | 329 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 339 |
| Rheumatoid Arthritis (RA): Glucocorticoid ManagementAs Medicare defines this measure | 100% | 31 |
| Rheumatoid Arthritis (RA): Periodic Assessment of Disease ActivityAs Medicare defines this measure | 100% | 38 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 100% | 341 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 330 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Implementation of practices/processes for developing regular individual care plans
- Implementation of Use of Specialist Reports Back to Referring Clinician or Group to Close Referral Loop
Professional record
- NPI
- 1972780146
- Licence
- CA A121284, MD P22025California A121284: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 1079 Eucalyptus St, Suite A, Manteca, CA, 95337
- NPI first listed
- 2008-01-30
- NPI last updated
- 2025-04-15
- NPI record certified
- 2025-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 6600 Madison Avenue, Carmichael, CA, 95608 · 530 W Eaton Avenue, Tracy, CA, 95376